Cencora, Inc. (NYSE:COR) Receives $275.60 Average PT from Brokerages

Shares of Cencora, Inc. (NYSE:COR) have earned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $275.60.

COR has been the subject of a number of analyst reports. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Finally, Wells Fargo & Company cut their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 over the last three months. Company insiders own 15.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Lake Street Advisors Group LLC boosted its stake in Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after buying an additional 43 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Cencora by 1.0% during the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after purchasing an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its holdings in shares of Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after purchasing an additional 46 shares during the last quarter. J.W. Cole Advisors Inc. lifted its holdings in shares of Cencora by 1.3% during the third quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after purchasing an additional 48 shares during the last quarter. Finally, Impact Partnership Wealth LLC lifted its holdings in shares of Cencora by 2.6% during the third quarter. Impact Partnership Wealth LLC now owns 2,042 shares of the company’s stock valued at $460,000 after purchasing an additional 51 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.5 %

NYSE COR opened at $242.11 on Tuesday. The stock has a market cap of $46.80 billion, a PE ratio of 32.24, a P/E/G ratio of 1.48 and a beta of 0.49. Cencora has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The business has a 50 day moving average price of $237.52 and a two-hundred day moving average price of $233.93. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.91%. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.